Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the UK and the US.

Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the UK and the US. Br J Dermatol. 2019 Aug 22;: Authors: Andersen L, Nyeland ME, Nyberg F Abstract BACKGROUND: Better understanding of the relationship between atopic dermatitis (AD) severity and health-related quality of life (HRQoL) could help improve knowledge about the benefits of a more effective treatment of people with AD. OBJECTIVES: To assess the relationship between AD severity and HRQoL as well as with perception of AD symptoms, among adults with moderate-to-severe AD in Europe (France, Germany, and the UK) and the US. METHODS: The survey panel participants for this cross-sectional, internet-based survey in AD adults were recruited from the larger population-based National Health and Wellness Survey (NHWS) (2016 Europe and 2015-2016 US). AD severity was measured by Patient-Oriented SCORing of AD (PO-SCORAD). HRQoL was measured by the 5-level EuroQol-5D version (EQ-5D-5L), Dermatology Life Quality Index (DLQI), and Patient-Oriented Eczema Measure (POEM). RESULTS: 1,232 respondents were included: 1,098 (89.1%) with moderate-to-severe AD (221 [20.1%] from France, 209 [19.0%] Germany, 118 [10.7%] UK, and 550 [50.1%] US); and an additional 134 (10.9%) respondents with mild AD. Sociodemographic and clinical AD characteristics were similar between countries. Among adults with moder...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research

Related Links:

Authors: Allais B, Friedman A Abstract Colloidal oatmeal has a diverse array of applications, clinical benefits, and uses beyond atopic dermatitis. First and foremost, it has been shown to be of benefit in the treatment of atopic dermatitis in skin of color. It has also been shown to be of benefit in the treatment of hand dermatitis, xerosis, psoriasis, skin manifestations of diabetes, and in the treatment of cutaneous adverse effects associated with oncologic therapies. In Part II of this 2-part series, we examine the efficacy, safety, and expansive clinical applications of colloidal oatmeal. J Drugs Dermatol. 202...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Authors: Utley C, Gold MH, Hall M Abstract Background/Significance of problem: Atopic Dermatitis (AD) is a common, chronic, inflammatory dermatosis and skin disease that follows a relapsing pattern and requires a dynamic stepwise approach to management.Providers feel comfortable treating chronic disease states with a guided tool or care plan in many chronic diseases.Care plans used in many chronic diseases such as asthma, diabetes, and COPD have demonstrated effectiveness in disease and healthcare provider management.There is an unmet need for a universal AD care plan for providers. Clinical question/project purpos...
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
Discussion Herpes simplex virus (HSV) infections are common with an estimated 50% of the US population being infected by age 30, and with latent infection harboring in the trigeminal nerve in 100% of people by age 60 years. HSV infections can cause a vesicular or pustular skin rash that is painful, burning or pruritic and also flu-like symptoms with fever, chills, headache, and fatigue. HSV can also be asymptomatic. To laymen, herpes simplex viruses cause “cold sores,” but to health care personnel, herpes causes many systemic infections including eczema herpeticum, folliculitis, herpes gladiatorum, whitlow, e...
Source: PediatricEducation.org - Category: Pediatrics Authors: Tags: Uncategorized Source Type: news
ABSTRACTAtopic dermatitis (AD) is an incurable, inflammatory skin condition that is prevalent ( ∼20%) in young children. There is an unmet clinical need, particularly in children, for safe interventions that target the etiology of the disease. Deficiencies in the skin barrier protein, filaggrin (FLG) have been identified as major predisposing factors in AD. In mammals,l-histidine is rapidly incorporated into epidermal FLG and subsequent FLG proteolysis releasesl-histidine as an important natural moisturizing factor (NMF). It has therefore been hypothesized thatl-histidine supplementation would be a safe approach to aug...
Source: Journal of Nutrition - Category: Nutrition Source Type: research
Contributors : Weng-Sheng Kong ; Masamoto KannoSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusBreastfeeding is thought to influence the immune system development of infants and may even affect various immunological responses later in life. Breast milk provides a rich source of early nutrition for the growth and developmental of infants. However, the presence of certain compounds in breast milk related to an unhealthy lifestyle or the diet of lactating mothers may negatively impact infants6. Based on a cohort study, we found that the composition of mother ’s milk containing high...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
CONCLUSIONS: There were substantial differences of agreement, suggesting there are many knowledge and/or practice gaps with respect to CHE. Future research is needed to inform evidence-based and/or consensus guidelines for CHE. PMID: 32991335 [PubMed - as supplied by publisher]
Source: Dermatitis - Category: Dermatology Authors: Tags: Dermatitis Source Type: research
Abstract BACKGROUND: Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13, a key driver of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of tralokinumab in combination with TCS in patients with moderate-to-severe AD who were candidates for systemic therapy. METHODS: This was a double-blind, placebo plus optional TCS-controlled phase III trial. Patients were randomized 2 : 1 to subcutaneous tralokinumab 300 mg or placebo every 2 weeks (Q2W) with TCS as needed over 16 weeks. Patients who achieved an Investigator's Global Assessment (I...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2020 Sep 30;: Authors: Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, Østerdal ML, Simpson EL Abstract BACKGROUND: Tralokinumab, a fully human monoclonal antibody, specifically neutralizes interleukin-13, a key cytokine driving per...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
CONCLUSIONS: Our study showed that the frequency and severity of some dermatological complaints increased in HCPs. PMID: 32975297 [PubMed - in process]
Source: Acta Dermatovenerologica Alpina, Panonica, et Adriatica - Category: Dermatology Tags: Acta Dermatovenerol Alp Pannonica Adriat Source Type: research
Dupilumab provides favourable long-term safety and efficacy in children aged ≥ 6 to
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
More News: Dermatitis | Dermatology | Eczema | France Health | Germany Health | Internet | Skin | UK Health